Cysteine addiction in drug resistant glioblastoma and therapeutic targeting with designer selenium compounds
Neuro-Oncology · 2026
DOI: 10.1093/neuonc/noaf265 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, 2026. Verfasst von Deanna Tiek und 16 weiteren Autor:innen. Beteiligte Einrichtung: The Ken & Ruth Davee Department of Neurology, The Lou and Jean Malnati Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Simpso…. Hauptthemen laut MEDLINE: Glioblastoma, Drug Resistance, Neoplasm, Cysteine, Brain Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Zell Scholar at Northwestern University, Northwestern University Feinberg School of Medicine Lurie Cancer Center Metabolomics Core, NCI NIH HHS.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
AbstractAbstract Background Cysteine is a multifunctional amino acid that can be oxidized affecting disulfide bond formation, redox signaling, and protein function. Reactive oxygen species (ROS) and the metabolic environment dictate cysteine uptake and oxidation status—especially in redox sensitive pathways. As many chemotherapeutic agents increase ROS, including the standard care for glioblastoma (GBM), temozolomide (TMZ), we hypothesized that TMZ-resistant (TMZ-R) GBM would have increased ROS affecting cysteine reactivity that could be therapeutically targeted.
Methods
Here, to study the metabolic state within drug sensitive and resistant GBM, we used metabolite tracing with13 C-Cyst(e)ine, specialized cysteine reactivity proteomics and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) screening with drug treatments to determine the efficacy of targeting cysteine metabolic pathways with our designer selenium drug in both patient-derived cell lines and patient-derived xenograft GBM orthotopic models.
Results
We show that TMZ-R have increased cyst(e)ine uptake, cysteine reactivity, and sensitivity to selenium (Se)-containing compounds—which can bind cysteine—in vitro and in vivo. We show that in TMZ-R models selenium compound treatment increases the need for thioredoxin reductases where co-treatment of Se compounds and the thioredoxin inhibitor auranofin significantly improves overall survival in mouse models.
Conclusions
Overall, our findings show a unique metabolic environment in TMZ-R models where designer brain penetrant Se-containing compounds target cysteine reactivity within proteins necessary for cancer cell survival and hold therapeutic potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Ken & Ruth Davee Department of Neurology, The Lou and Jean Malnati Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Simpson Querrey Institute for Epigenetics, Northwestern University Feinberg…
- Department of Cancer Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland (D.T.).
- High-Throughput Analysis Laboratory, Chemistry of Life Processes Institute, Northwestern University, Evanston (Y.M.).
- Department of Chemistry, Northwestern University, Evanston (A.M., X.Z.).
- Department of Molecular and Precision Medicine, Penn State Cancer Institute, Penn State College of Medicine, Hershey (A.S., A.K.S.).
- Department of Neuroscience and Experimental Therapeutics, Penn State Cancer Institute, Penn State College of Medicine, Hershey (J.L.).
ORCID-Profile: Bo Hu, Shi-Yuan Cheng
Förderung
- Zell Scholar at Northwestern University
- Northwestern University Feinberg School of Medicine Lurie Cancer Center Metabolomics Core
- NCI NIH HHS
- Lou and Jean Malnati Brain Tumor Institute at Northwestern Medicine
- NIH HHS
- NINDS NIH HHS
- NIGMS NIH HHS
- National Institutes of Health
Zitieren
APA
Tiek, D., Song, X., Wu, R., Yu, X., Walker, M., Mao, Y., Sisbarro, D., He, Q., Magassa, A., Singh, A., Lu, J., Sharma, A. K., Miska, J., Hu, B., Bonini, M. G., Zhang, X., & Cheng, S. Y. (2026). Cysteine addiction in drug resistant glioblastoma and therapeutic targeting with designer selenium compounds. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf265
Vancouver
Tiek D, Song X, Wu R, Yu X, Walker M, Mao Y, et al. Cysteine addiction in drug resistant glioblastoma and therapeutic targeting with designer selenium compounds. Neuro-Oncology. 2026. doi:10.1093/neuonc/noaf265
BibTeX
@article{Tiek2026,
author = {Tiek, Deanna and Song, Xiao and Wu, Runxin and Yu, Xiaozhou and Walker, Maya and Mao, Yingyu and Sisbarro, Derek and He, Qiu and Magassa, Assa and Singh, Amandeep and Lu, Junxuan and Sharma, Arun K and Miska, Jason and Hu, Bo and Bonini, Marcelo G and Zhang, Xiaoyu and Cheng, Shi-Yuan},
title = {Cysteine addiction in drug resistant glioblastoma and therapeutic targeting with designer selenium compounds},
journal = {Neuro-Oncology},
year = {2026},
doi = {10.1093/neuonc/noaf265}
}
EUVIMED